Investing.com - Cara Therapeutic (NASDAQ: CARA) reported third quarter EPS of $-0.52, in line with the analyst estimate of $-0.52. Revenue for the quarter came in at $4.87M versus the consensus estimate of $9.95M.
Cara Therapeutic's stock price closed at $1.18. It is down -60.80% in the last 3 months and down -89.41% in the last 12 months.
Cara Therapeutic saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Cara Therapeutic's stock price’s past reactions to earnings here.
According to InvestingPro, Cara Therapeutic's Financial Health score is "weak performance".
Check out Cara Therapeutic's recent earnings performance, and Cara Therapeutic's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar